Skip to main content
OpenTrials
Completed

NCT Number: NCT01923519

Study of Genic Expression Profiles of the Epithelium of the Nose and Bronchi in Healthy and Allergic Subjects

The respiratory epithelium plays a leading role in the development of allergic respiratory disease with barrier function alteration, its repair mechanisms, of anti-viral fight and the ability to induce by itself Th2 responses. The majority of allergic asthmatic patients have reached concomitant ENT: the concept of "one airway, one disease." Access to this material of epithelial study in the different phenotypes of the disease appears to be crucial. Nasal and bronchial epithelial tissues reveal essential differences in particular related to their environment (remodeling less intense and a lower sensitivity to the virus in the nose), but they nevertheless share many common cellular characteristics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Allergy Hypersensitivity Immune System Diseases

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital Pasteur

Nice, 06003, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age ≥ 18 years and <30 years
  • isolated allergic rhinitis according to clinical criteria ARIA
  • absence of asthma whose diagnosis is made based on clinical criteria or mild to moderate persistent asthma controlled with a diagnosis is made based on clinical criteria

Exclusion criteria

  • recent rhino-bronchial infection (<6 weeks)
  • asthma exacerbation in the previous 6 weeks
  • Chronic disease may in the opinion of the investigators interfere with the results of the study or expose them to additional risk.
  • Treatment with nasal corticosteroids, inhaled or systemic in the past 6 weeks
  • Current smoking no history of smoking or not smoking for at least 12 months and weaned smoking history <5 pack-years)
  • Special Needs

Treatment and study plan

bronchofiberscopy

Procedure

Primary outcomes

  1. genic expression profile of the epithelium

    Time frame: 3 months after inclusion

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nice

Other

Registry information

Acronym: GENEBRO

Important dates

Study start
2013
Primary completion
2016
Study completion
2017
First posted
Aug 15, 2013
Registry last updated
Mar 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.